Skip to main
AGEN

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Agenus Inc presents a favorable outlook due to its robust pipeline of therapies aimed at activating the immune system to combat cancer, supported by in-house capabilities including cGMP manufacturing and clinical operations. The compassionate use of the company’s antibody candidates, botensilimab and balstilimab, is anticipated to create an additional revenue stream while generating real-world clinical evidence to bolster their applications. Furthermore, positive early regulatory sentiment regarding these therapies in indications such as triple-negative breast cancer and microsatellite-stable colorectal cancer contributes to the overall growth potential of the company.

Bears say

Agenus Inc faces several significant risks that contribute to a negative outlook on its stock. These include potential safety signals arising from clinical or preclinical programs, lower-than-expected efficacy from trials, and increased competition from other treatments. Additionally, concerns regarding regulatory challenges, financing needs, and intellectual property protection further compound the uncertainty surrounding the company's financial stability and growth prospects.

Agenus (AGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Agenus (AGEN) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.